Abstract
Linking the molecular aberrations of cancer to drug responses could guide treatment choice and identify new therapeutic applications. However, there has been no systematic approach for analyzing gene-drug interactions in human cells. Here we establish a multiplexed assay to study the cellular fitness of a panel of engineered isogenic cancer cells in response to a collection of drugs, enabling the systematic analysis of thousands of gene-drug interactions. Applying this approach to breast cancer revealed various synthetic-lethal interactions and drug-resistance mechanisms, some of which were known, thereby validating the method. NOTCH pathway activation, which occurs frequently in breast cancer, unexpectedly conferred resistance to phosphoinositide 3-kinase (PI3K) inhibitors, which are currently undergoing clinical trials in breast cancer patients. NOTCH1 and downstream induction of c-MYC over-rode the dependency of cells on the PI3K-mTOR pathway for proliferation. These data reveal a new mechanism of resistance to PI3K inhibitors with direct clinical implications.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615–627 (2002).
Trédan, O., Galmarini, C.M., Patel, K. & Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441–1454 (2007).
Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
McDermott, U., Downing, J.R. & Stratton, M.R. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340–350 (2011).
Bernards, R. It's diagnostics, stupid. Cell 141, 13–17 (2010).
Chin, L. & Gray, J.W. Translating insights from the cancer genome into clinical practice. Nature 452, 553–563 (2008).
Lander, E.S. Initial impact of the sequencing of the human genome. Nature 470, 187–197 (2011).
Vogel, C.L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
Deming, S.L., Nass, S.J., Dickson, R.B. & Trock, B.J. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer 83, 1688–1695 (2000).
Verdine, G.L. & Walensky, L.D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264–7270 (2007).
Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
Kaelin, W.G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689–698 (2005).
Nijman, S.M. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 585, 1–6 (2011).
Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
Fong, P.C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512–2519 (2010).
Reinhardt, H.C., Jiang, H., Hemann, M.T. & Yaffe, M.B. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8, 3112–3119 (2009).
Hillenmeyer, M.E. et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320, 362–365 (2008).
Lum, P.Y. et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116, 121–137 (2004).
Workman, P., Clarke, P.A., Raynaud, F.I. & van Montfort, R.L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 70, 2146–2157 (2010).
Liu, P., Cheng, H., Roberts, T.M. & Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627–644 (2009).
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001).
Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515–527 (2006).
Iavarone, A. & Massague, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 387, 417–422 (1997).
Yang, D. et al. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. USA 107, 13836–13841 (2010).
Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851–1863 (2008).
Jarriault, S. et al. Signalling downstream of activated mammalian Notch. Nature 377, 355–358 (1995).
Laplante, M. & Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci. 122, 3589–3594 (2009).
Feldman, M.E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
Serra, V. et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022–8030 (2008).
Pece, S. et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 167, 215–221 (2004).
Klinakis, A. et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl. Acad. Sci. USA 103, 9262–9267 (2006).
Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 103, 18261–18266 (2006).
Weng, A.P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20, 2096–2109 (2006).
Reedijk, M. et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 65, 8530–8537 (2005).
Lin, C.J., Malina, A. & Pelletier, J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 69, 7491–7494 (2009).
Ruggero, D. & Pandolfi, P.P. Does the ribosome translate cancer? Nat. Rev. Cancer 3, 179–192 (2003).
Fojo, T. & Grady, C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 101, 1044–1048 (2009).
Brachmann, S.M. et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA 106, 22299–22304 (2009).
Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283–1298 (2006).
Stegmaier, K. et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 4, e122 (2007).
Acknowledgements
We thank the T. Berg, A. Harutyunyan, U. Rix and G. Hofbauer for technical assistance; F. Ganglberger, B. Eizinger and P. Markt for assisting in data analysis; and H. Pickersgill, M. Creyghton and G. Superti-Furga for critical reading and suggestions. We are grateful to T. Golub and C. Yu for support and discussions in the early phases of the project; and to A. D'Andrea, H. Dolznig, C. Tabin, T. Brummelkamp, R. Bernards, P. Eichhorn, D. Peeper, W. Hahn, R. Conaway, J. Conaway, R. Weinberg, I. Screpanti, J. Zhao, R. Hynes, Y. Xiong, R. Basch, B. Vogelstein, D. Bulavin, P. Yaswen, R. Kopan, M. Parker, J. Bradner and D. Root for providing reagents. We thank Luminex for providing reagents and support. This work was made possible by research grants from the Austrian Science Fund (FWF, P21768-B13) and the Vienna Science and Technology Fund (WWTF, LS09-009).
Author information
Authors and Affiliations
Contributions
S.M.B.N. and M.K.M. conceived the study, designed experiments, analyzed data and wrote the manuscript. M.K.M. and S.M.B.N., with help from I.Z.U. and N.C.-M., set up the multiplexing assay. B.V.G., I.Z.U and M.K.M. created and characterized the isogenic cell lines. J.C. and G.D. designed the analysis platform and database infrastructure for the screen. G.D. and M.K.M. analyzed the screening data and wrote R code to identify hits. M.K.M. performed the majority of experiments. C.K., M.S., H.L. and S.M.B.N. performed and helped with additional experiments.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods and Supplementary Results (PDF 6912 kb)
Rights and permissions
About this article
Cite this article
Muellner, M., Uras, I., Gapp, B. et al. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol 7, 787–793 (2011). https://doi.org/10.1038/nchembio.695
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.695
This article is cited by
-
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
Scientific Reports (2024)
-
Target identification of small molecules: an overview of the current applications in drug discovery
BMC Biotechnology (2023)
-
Recent advances in therapeutic strategies for triple-negative breast cancer
Journal of Hematology & Oncology (2022)
-
Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells
Cell Death & Disease (2021)
-
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Molecular Cancer (2019)